ADH -1 (Exherin™)

DRUG3 trials

Sponsors

Adherex Technologies, Inc.

Conditions

Neoplasms

Phase 1

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

TerminatedNCT00225550

Adherex Technologies, Inc.Neoplasms

Updated: 2007-08-06

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

CompletedNCT00265057

Adherex Technologies, Inc.Neoplasms

Start: 2005-06-30End: 2008-01-31Updated: 2010-12-28

Phase 2

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

CompletedNCT00264433

Adherex Technologies, Inc.Neoplasms

Updated: 2007-08-06